Teva stock targets $6-7 billion in innovative medicines by 2030

Teva Pharmaceutical Industries presented its next growth phase at its first R&D Day on Wednesday, November 11, 2026. The company said its strategy is designed to turn a broader pipeline and commercial platform into sustained biopharmaceutical growth.

In a Teva Investor Relations release, President and CEO Richard Francis said the company has more than doubled innovative-medicines revenue since launching its Pivot to Growth strategy in 2023. Teva said its late-stage pipeline has more than 10 billion US dollars in potential peak sales, before regulatory approval and without risk adjustment.

Pipeline and financial priorities

Teva highlighted a potential for one innovative-medicine launch annually through 2030. Its longer-term research programs include an anti-IL-15 asset, the investigational anti-PD-1/IL-2 treatment ATTENUKINE and next-generation antibodies aimed at areas such as asthma and inflammatory bowel disease.

Management expects mid-single-digit total revenue growth from 2026 through 2030 and is targeting innovative gross margins above 75 percent. Teva also set a free-cash-flow target above 3.5 billion US dollars by 2030 and outlined a path to reduce net debt to adjusted EBITDA to 2.0 times by the end of 2027. These are company targets and depend on development, regulatory and commercial execution.

The Israeli market backdrop remains relevant for investors following Teva stock; see the TA-35 market reports.

For investors, the strategy shifts attention toward the pace of pipeline advancement, launch execution and the balance between innovative medicines, generics and biosimilars. More news and analyses on Teva stock.